Kazia Therapeutics Ltd ADR Stock
Kazia Therapeutics Ltd ADR
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- CEO
- John Friend
- Employees
- 6
- Market cap
- $12 M
- IPO
- 06/01/1999
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which…
Kazia Therapeutics Ltd ADR stock: price history
1D
-2.0%
1W
-18.8%
1M
-28.9%
6M
-34.7%
YTD
+5.2%
1Y
+3.7%
2Y
-56.5%
5Y
-98.6%
10Y
-98.0%
Next earnings date
Next earnings date
02/03/2027 (in 136 days)
Volatility around earnings
~4% weaker price swings than usual
Ask the agents about Kazia Therapeutics Ltd ADR
Analyst assessment of Kazia Therapeutics Ltd ADR
PRICE TARGET LOW
US$29.00
CONSENSUS
US$33.67
MEDIAN
US$32.00
PRICE TARGET HIGH
US$40.00
0
STRONG BUY
3
BUY
0
HOLD
0
SELL
0
STRONG SELL
3
TOTAL · Buy
As of: 10/09/2026
Kazia Therapeutics Ltd ADR stock metrics
P/E
-1.01
P/B
0.7
EV/EBITDA
2.89
RETURN ON EQUITY
-26.5%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
31/12/2025
Free float & liquidity
FREE FLOAT
98.6%
FLOAT SHARES
1,596,644
AVG. DAILY VOLUME (30D)
287,198
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Kazia Therapeutics Ltd ADR stock
What does Kazia Therapeutics Ltd ADR do?
Kazia Therapeutics Ltd ADR is a company in the Healthcare sector, Biotechnology industry, headquartered in Australia.
The CEO is John Friend, the company employs around 6 people.
The IPO was on 06/01/1999; the stock trades on NASDAQ under the ticker KZIA.
What do analysts say about Kazia Therapeutics Ltd ADR stock?
3 analysts rate the stock, the consensus is Buy (as of 10/09/2026).
The average price target is US$33.67, ranging from US$29.00 to US$40.00, with a median of US$32.00.
This is an external assessment, not a statement by Market Jury.
When does Kazia Therapeutics Ltd ADR report next?
The next earnings date is 02/03/2027.
Around past earnings, price swings were roughly -4% stronger than usual.
Does Kazia Therapeutics Ltd ADR pay a dividend?
No, Kazia Therapeutics Ltd ADR currently does not pay a dividend.
Which stocks are comparable to Kazia Therapeutics Ltd ADR?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Kazia Therapeutics Ltd ADR stock analyzed?
Clicking "Analyze stock" lets five strategies assess Kazia Therapeutics Ltd ADR against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.